REPCF (0913693 BC) Debt-to-Equity: -0.01 (As of Sep. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is 0913693 BC Debt-to-Equity?

0913693 BC REPCF Debt-to-Equity is -0.01 as of Sep. 2023.

0913693 BC's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $0.00 Mil. 0913693 BC's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $0.03 Mil. 0913693 BC's Total Stockholders Equity for the quarter that ended in Sep. 2023 was $-4.91 Mil. 0913693 BC's debt to equity for the quarter that ended in Sep. 2023 was -0.01.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for 0913693 BC's Debt-to-Equity or its related term are showing as below:

REPCF's Debt-to-Equity is not ranked *
in the Biotechnology industry.
Industry Median: 0.16
* Ranked among companies with meaningful Debt-to-Equity only.

0913693 BC  (OTCPK:REPCF) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

0913693 BC Debt-to-Equity Related Terms

0913693 BC Debt-to-Equity Historical Data

* Premium members only.

The historical data trend for 0913693 BC's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

0913693 BC Debt-to-Equity Chart

0913693 BC Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 -0.02 -0.01 -0.01

0913693 BC Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.00 -0.01 -0.01 -0.01 -0.01

REPCF vs VRTX, REGN, SGEN: Debt-to-Equity Comparison

For the Biotechnology subindustry, 0913693 BC's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

0913693 BC Debt-to-Equity vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 0913693 BC's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where 0913693 BC's Debt-to-Equity falls into.


0913693 BC Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

0913693 BC's Debt to Equity Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0 + 0.03) / -4.354
=-0.01

0913693 BC's Debt to Equity Ratio for the quarter that ended in Sep. 2023 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0 + 0.03) / -4.905
=-0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Equity →
What does a Debt-to-Equity of -0.01 mean?
0913693 BC (REPCF) has a Debt-to-Equity of -0.01 as of Sep. 2023. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on 0913693 BC and its competitors.
Is 0913693 BC's Debt-to-Equity too high?
0913693 BC's current Debt-to-Equity is -0.01.
How does 0913693 BC's Debt-to-Equity compare to VRTX and REGN?
0913693 BC's Debt-to-Equity of -0.01 can be compared against companies in the Biotechnology industry. The industry median Debt-to-Equity is 0.16. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 966 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on 0913693 BC and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. 0913693 BC's current Debt-to-Equity is -0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 0913693 BC stock overvalued right now?
0913693 BC (REPCF) has a current Debt-to-Equity of -0.01. The current Debt-to-Equity is -0.01. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For 0913693 BC (REPCF), the current Debt-to-Equity is -0.01 as of Sep. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

0913693 BC Business Description

Address 570 Granville Street, Suite 900, Vancouver, BC, CAN, V6C 3P1
0913693 BC Ltd is a regenerative medicine company focused on aesthetics and orthopedics. It is a royalty company that holds its primary royalty assets focused on autologous cell therapies that treat functional cellular deficits, including chronic tendon injuries, androgenetic alopecia, and skin aging. The Company is organized into one business unit based on its cell replication technology and has one reportable operating segment. Its product line is RCT-01 Tendon Repair, RCS-01 Skin Rejuvenation, RCH-01 Hair Growth, and DermaPrecise.